Q1 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – HC Wainwright issued their Q1 2025 earnings estimates for Annexon in a report issued on Tuesday, March 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.28) EPS.

Annexon (NASDAQ:ANNX) last released its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05).

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Stock Up 3.0 %

Annexon stock opened at $2.76 on Friday. The company has a market cap of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14. The firm’s fifty day moving average is $3.75 and its 200 day moving average is $5.34. Annexon has a 52-week low of $2.30 and a 52-week high of $8.40.

Hedge Funds Weigh In On Annexon

A number of institutional investors have recently bought and sold shares of the business. Parkman Healthcare Partners LLC raised its position in Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after buying an additional 1,768 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Annexon by 1.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after buying an additional 2,450 shares during the last quarter. GSA Capital Partners LLP raised its position in Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after buying an additional 3,355 shares during the last quarter. E Fund Management Co. Ltd. raised its position in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after buying an additional 4,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Annexon by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after buying an additional 4,092 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.